News

pharmaphorum3d
Pfizer pulls sickle cell med Oxbryta off market after deaths
Pfizer is voluntarily withdrawing its sickle cell disease (SCD) therapy Oxbryta from all world markets after finding an "imbalance" in deaths in its clinical trials programme. It's a blow to the ...
pharmaphorum6d
Pfizer vaults into sickle cell market as GBT deal confirmed
Pfizer's reported interest in acquiring sickle cell disease specialist Global Blood Therapeutics (GBT) has been confirmed, with the $68.50-per-share deal valuing GBT at $5.4 billion.
Sickle Cell Disease Treatment Market Set For Robust Growth Through 2034, Driven By Recent Clinical Pipeline Developments Delveinsight
Sickle Cell Disease Market Insight, Epidemiology And Market Forecast - 2034The sickle cell disease treatment market is experiencing signific ...
Yahoo Finance3d
Pfizer Inc. (PFE) Stock Price, News, Quote & History - Yahoo Finance
PFE Pfizer Inc. 25.04 +3.30% Mkt Cap 142.362B IndustryDrug Manufacturers—General MRK Merck & Co., Inc. 81.81 +3.35% Mkt Cap 205.427B IndustryDrug Manufacturers—General JNJ Johnson & Johnson 155.92 ...
Yahoo Finance2d
Pfizer Inc. (PFE)
PFE Pfizer Inc. 25.32 +1.12% Mkt cap 143.954B IndustryDrug Manufacturers—General MRK Merck & Co., Inc. 82.39 +0.71% Mkt cap 206.884B IndustryDrug Manufacturers—General JNJ Johnson & Johnson 155.56 ...